<p>Trevi Therapeutics, Inc.（纳斯达克代码：TRVI - 获取免费报告）在目前覆盖该公司的十家评级机构中获得了 “买入” 的平均推荐，Marketbeat 报道称。一位分析师给予该股票卖出评级，七位分析师给予买入评级，另外两位分析师给予强烈买入评级。在过去一年中，覆盖该股票的经纪商的平均一年目标价格为 21.4444 美元。</p>
<p>获取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
<p>几家券商最近对 TRVI 进行了评估。B. Riley 在 11 月 17 日的研究报告中将 Trevi Therapeutics 的股票评级提升至 “强烈买入”。Oppenheimer 在 11 月 14 日的报告中将 Trevi Therapeutics 的目标价格从 23.00 美元提高至 24.00 美元，并给予该股票 “跑赢大盘” 的评级。摩根士丹利在 11 月 14 日的研究报告中将 Trevi Therapeutics 的目标价格从 18.00 美元提高至 19.00 美元，并给予该公司 “增持” 的评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Trevi Therapeutics 的 “卖出（d-）” 评级。最后，D. Boral Capital 在 11 月 14 日的研究报告中重新发布了 “买入” 评级，并将 Trevi Therapeutics 的目标价格设定为 19.00 美元。</p>
<p><strong>查看我们对 TRVI 的最新股票分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近买入和卖出了 TRVI 的股票。拉塞尔投资集团在第二季度将其在 Trevi Therapeutics 的股份增加了 194.5%。拉塞尔投资集团现在拥有 4536 股该公司的股票，价值 25000 美元，此前在上个季度又购买了 2996 股。BIT Capital GmbH 在第三季度将其在 Trevi Therapeutics 的持仓增加了 32.0%。BIT Capital GmbH 现在拥有 6739 股该公司的股票，价值 62000 美元，此前在上个季度又收购了 1633 股。Ameritas Investment Partners Inc. 在第三季度将其在 Trevi Therapeutics 的持仓增加了 20.5%。Ameritas Investment Partners Inc. 现在拥有 7632 股该公司的股票，价值 70000 美元，此前在上个季度又收购了 1300 股。Strs Ohio 在第一季度收购了 Trevi Therapeutics 的新股份，价值 52000 美元。最后，AlphaQuest LLC 在第三季度收购了 Trevi Therapeutics 的新股份，价值 80000 美元。目前 95.76% 的股票由机构投资者持有。</p>
<h2>Trevi Therapeutics 股价下跌 2.4%</h2>
<p>TRVI 股票在周四开盘价为 12.11 美元。该股票的 50 日移动平均价格为 11.61 美元，200 日移动平均价格为 8.81 美元。Trevi Therapeutics 的一年低点为 3.47 美元，一年高点为 14.39 美元。该股票的市值为 15.5 亿美元，市盈率为-32.73，贝塔值为 0.83。</p>
<p>Trevi Therapeutics（纳斯达克代码：TRVI - 获取免费报告）最近于 11 月 13 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.08 美元，超出分析师的共识预期（-0.10 美元）0.02 美元。分析师平均预测 Trevi Therapeutics 本财年的每股收益将为-0.49 美元。</p>
<h2>Trevi Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Trevi Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化 Haduvio 治疗方案，用于治疗特发性肺纤维化（IPF）和难治性慢性咳嗽（RCC）等疾病，目标是中央和外周神经系统。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Trevi Therapeutics 更好</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>在股价上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>如何在购买前评估一只股票</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的主要催化剂</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Trevi Therapeutics 吗？</h2>
<p>在考虑 Trevi Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Trevi Therapeutics 并不在名单上。</p>
<p>虽然 Trevi Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TRVI

<p>Trevi Therapeutics, Inc.（纳斯达克代码：TRVI）获得了分析师一致的 “买入” 评级，其中包括一项卖出评级、七项买入评级和两项强买入评级。平均一年目标价为 21.44 美元。最近的分析师行动包括 B. Riley 的强买入评级和 Oppenheimer 将目标价上调至 24.00 美元。机构投资者持有该股票的 95.76%，该股票最近交易下跌 2.4%，至 12.11 美元</p>

<p>Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average recommendation of &#34;Buy&#34; from the ten ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $21.4444.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc.（纳斯达克代码：TRVI - 获取免费报告）在目前覆盖该公司的十家评级机构中获得了 “买入” 的平均推荐，Marketbeat 报道称。一位分析师给予该股票卖出评级，七位分析师给予买入评级，另外两位分析师给予强烈买入评级。在过去一年中，覆盖该股票的经纪商的平均一年目标价格为 21.4444 美元。</p>
</div><p>Get <strong>Trevi Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
</div><p>Several brokerages have recently weighed in on TRVI. B. Riley raised shares of Trevi Therapeutics to a &#34;strong-buy&#34; rating in a research note on Monday, November 17th. Oppenheimer increased their target price on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, November 14th. Morgan Stanley raised their target price on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, November 14th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Trevi Therapeutics in a research note on Wednesday, October 8th. Finally, D. Boral Capital reissued a &#34;buy&#34; rating and set a $19.00 price target on shares of Trevi Therapeutics in a research report on Friday, November 14th.</p>
<div class="lb-trans"><p>几家券商最近对 TRVI 进行了评估。B. Riley 在 11 月 17 日的研究报告中将 Trevi Therapeutics 的股票评级提升至 “强烈买入”。Oppenheimer 在 11 月 14 日的报告中将 Trevi Therapeutics 的目标价格从 23.00 美元提高至 24.00 美元，并给予该股票 “跑赢大盘” 的评级。摩根士丹利在 11 月 14 日的研究报告中将 Trevi Therapeutics 的目标价格从 18.00 美元提高至 19.00 美元，并给予该公司 “增持” 的评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Trevi Therapeutics 的 “卖出（d-）” 评级。最后，D. Boral Capital 在 11 月 14 日的研究报告中重新发布了 “买入” 评级，并将 Trevi Therapeutics 的目标价格设定为 19.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on TRVI</strong></p>
<div class="lb-trans"><p><strong>查看我们对 TRVI 的最新股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently bought and sold shares of TRVI. Russell Investments Group Ltd. raised its stake in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock worth $25,000 after purchasing an additional 2,996 shares in the last quarter. BIT Capital GmbH raised its position in Trevi Therapeutics by 32.0% during the third quarter. BIT Capital GmbH now owns 6,739 shares of the company's stock worth $62,000 after acquiring an additional 1,633 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Trevi Therapeutics by 20.5% during the third quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company's stock worth $70,000 after acquiring an additional 1,300 shares in the last quarter. Strs Ohio acquired a new stake in Trevi Therapeutics in the first quarter valued at $52,000. Finally, AlphaQuest LLC acquired a new stake in Trevi Therapeutics in the third quarter valued at $80,000. 95.76% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了 TRVI 的股票。拉塞尔投资集团在第二季度将其在 Trevi Therapeutics 的股份增加了 194.5%。拉塞尔投资集团现在拥有 4536 股该公司的股票，价值 25000 美元，此前在上个季度又购买了 2996 股。BIT Capital GmbH 在第三季度将其在 Trevi Therapeutics 的持仓增加了 32.0%。BIT Capital GmbH 现在拥有 6739 股该公司的股票，价值 62000 美元，此前在上个季度又收购了 1633 股。Ameritas Investment Partners Inc. 在第三季度将其在 Trevi Therapeutics 的持仓增加了 20.5%。Ameritas Investment Partners Inc. 现在拥有 7632 股该公司的股票，价值 70000 美元，此前在上个季度又收购了 1300 股。Strs Ohio 在第一季度收购了 Trevi Therapeutics 的新股份，价值 52000 美元。最后，AlphaQuest LLC 在第三季度收购了 Trevi Therapeutics 的新股份，价值 80000 美元。目前 95.76% 的股票由机构投资者持有。</p>
</div><h2>Trevi Therapeutics Trading Down 2.4%</h2>
<div class="lb-trans"><h2>Trevi Therapeutics 股价下跌 2.4%</h2>
</div><p>TRVI stock opened at $12.11 on Thursday. The stock has a 50-day moving average price of $11.61 and a two-hundred day moving average price of $8.81. Trevi Therapeutics has a 1 year low of $3.47 and a 1 year high of $14.39. The stock has a market cap of $1.55 billion, a PE ratio of -32.73 and a beta of 0.83.</p>
<div class="lb-trans"><p>TRVI 股票在周四开盘价为 12.11 美元。该股票的 50 日移动平均价格为 11.61 美元，200 日移动平均价格为 8.81 美元。Trevi Therapeutics 的一年低点为 3.47 美元，一年高点为 14.39 美元。该股票的市值为 15.5 亿美元，市盈率为-32.73，贝塔值为 0.83。</p>
</div><p>Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. On average, analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Trevi Therapeutics（纳斯达克代码：TRVI - 获取免费报告）最近于 11 月 13 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.08 美元，超出分析师的共识预期（-0.10 美元）0.02 美元。分析师平均预测 Trevi Therapeutics 本财年的每股收益将为-0.49 美元。</p>
</div><h2>Trevi Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Trevi Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化 Haduvio 治疗方案，用于治疗特发性肺纤维化（IPF）和难治性慢性咳嗽（RCC）等疾病，目标是中央和外周神经系统。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Trevi Therapeutics</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Trevi Therapeutics 更好</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>在股价上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>如何在购买前评估一只股票</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的主要催化剂</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TRVI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Trevi Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Trevi Therapeutics 吗？</h2>
</div><p>Before you consider Trevi Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Trevi Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Trevi Therapeutics 并不在名单上。</p>
</div><p>While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Trevi Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Trevi Therapeutics, Inc. (NASDAQ:TRVI) 获得分析师一致给予 “买入” 评级